Xconomy: cancer News, Articles and Opinions

“cancer” Archives

Entry	Author	Date	Location
Gilliland to Step Down as Head of Fred Hutch in 2020	Jeff Buchanan	09/17/19	Seattle
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone	Frank Vinluan	09/06/19	National
Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D	Frank Vinluan	09/05/19	Boston
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More	Alex Lash	08/30/19	National
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop	Ben Fidler	08/29/19	Detroit Ann Arbor
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight	Ben Fidler	08/28/19	New York
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug	Frank Vinluan	08/23/19	National
Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing	Frank Vinluan	08/21/19	Boston
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More	Alex Lash	08/16/19	National
Four New Drugs Are Around the Corner. Here’s What You Need to Know.	Ben Fidler	08/15/19	National
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug	Ben Fidler	08/13/19	Boston
AIQ Solutions Hits On $3.2M to Pinpoint Drug-Resistant Tumors	Jeff Bauter Engel	08/07/19	Wisconsin
Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston	Angela Shah	07/31/19	National
Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D	Frank Vinluan	07/29/19	New York
Merck Data Are Another Step for Immunotherapy in Breast Cancer	Ben Fidler	07/29/19	New York
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More	Ben Fidler	07/26/19	National
As Castle Bio Jumps on IPO Train, Industry Trends Suggest Slowdown	Frank Vinluan	07/25/19	National
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck	Ben Fidler	07/24/19	New York
Freenome Snags $160M to Boost Blood Test for Early Cancer Detection	Bernadette Tansey	07/24/19	San Francisco
TScan Lands $48M for Better, Safer T-Cell Receptor Cancer Therapies	Frank Vinluan	07/24/19	Boston
Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More	Frank Vinluan	07/19/19	National
Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets	Frank Vinluan	07/18/19	San Francisco
Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts	Frank Vinluan	07/18/19	National
Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery	Frank Vinluan	07/16/19	Boston
Neon’s Early Vaccine Study Is a Peek at Immunotherapy’s Third Wave	Ben Fidler	07/15/19	Boston
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More	Alex Lash	07/12/19	National
After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs	Sarah de Crescenzo	07/09/19	San Francisco
BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut	Frank Vinluan	06/27/19	San Francisco
Mirati Stock Sale Targets $200M as Lead Cancer Drug Starts Phase 3	Sarah de Crescenzo	06/26/19	San Diego
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More	Frank Vinluan	06/21/19	National
Page 1 of 79	next page »